WO2000007580A3 - Pharmaceutical compositions against autoimmune diseases - Google Patents

Pharmaceutical compositions against autoimmune diseases Download PDF

Info

Publication number
WO2000007580A3
WO2000007580A3 PCT/HU1999/000054 HU9900054W WO0007580A3 WO 2000007580 A3 WO2000007580 A3 WO 2000007580A3 HU 9900054 W HU9900054 W HU 9900054W WO 0007580 A3 WO0007580 A3 WO 0007580A3
Authority
WO
WIPO (PCT)
Prior art keywords
autoimmune diseases
pharmaceutical compositions
against autoimmune
compositions against
formula
Prior art date
Application number
PCT/HU1999/000054
Other languages
French (fr)
Other versions
WO2000007580A2 (en
Inventor
Balazs Suemegi
Original Assignee
Gene Kutato Kft N
Balazs Suemegi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU9801772A external-priority patent/HU9801772D0/en
Priority claimed from HU9902398A external-priority patent/HUP9902398A3/en
Application filed by Gene Kutato Kft N, Balazs Suemegi filed Critical Gene Kutato Kft N
Priority to AU52967/99A priority Critical patent/AU5296799A/en
Publication of WO2000007580A2 publication Critical patent/WO2000007580A2/en
Publication of WO2000007580A3 publication Critical patent/WO2000007580A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention refers to the use of hydroximic acid derivatives of formula (I), wherein R?1, R2, R3¿, R, X, Y, A and B are as defined in the description, for the preparation of a pharmaceutical composition against autoimmune diseases.
PCT/HU1999/000054 1998-08-03 1999-08-02 Pharmaceutical compositions against autoimmune diseases WO2000007580A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU52967/99A AU5296799A (en) 1998-08-03 1999-08-02 Pharmaceutical compositions against autoimmune diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
HU9801772A HU9801772D0 (en) 1998-08-03 1998-08-03 Pharmaceutical composition
HUP9801772 1998-08-03
HUP9902398 1999-07-19
HU9902398A HUP9902398A3 (en) 1999-07-19 1999-07-19 Use of hydroxamic acid derivatives for preparation of medicaments against autoimmun illnesses

Publications (2)

Publication Number Publication Date
WO2000007580A2 WO2000007580A2 (en) 2000-02-17
WO2000007580A3 true WO2000007580A3 (en) 2000-05-18

Family

ID=89998777

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU1999/000054 WO2000007580A2 (en) 1998-08-03 1999-08-02 Pharmaceutical compositions against autoimmune diseases

Country Status (2)

Country Link
AU (1) AU5296799A (en)
WO (1) WO2000007580A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04000324A (en) * 2001-07-17 2004-07-23 N Gene Res Lab Inc A synergistic pharmaceutical combination for the prevention or treatment of diabetes.
US7763601B2 (en) 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1800298A1 (en) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Combination of beta blocker and hydroximic acid derivative with reduced side effects

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2362845A1 (en) * 1976-08-27 1978-03-24 Chinoin Gyogyszer Es Vegyeszet NEW O- (3-AMINO-2-HYDROXY-PROPYL) -AMIDOXIME DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO1990004584A1 (en) * 1988-10-20 1990-05-03 Biorex Kutató Fejleszto^' Kft. Novel o-(3-amino-2-hydroxypropyl)-hydroximic acid halides and process for preparing the same
WO1997013504A1 (en) * 1995-09-29 1997-04-17 Medgene Limited Pharmaceutical compositions containing hydroximic acid derivatives
WO1997016439A1 (en) * 1995-11-02 1997-05-09 Biorex Kutató és Fejlesztó Rt. Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof
DE19756236A1 (en) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Novel piperazinyl-substituted pyridylalkane, alkene and alkyarboxylic acid amides
DE19818044A1 (en) * 1998-04-22 1999-10-28 Klinge Co Chem Pharm Fab Reducing side effects or neutralizing action of carcinostatic or immunosuppressive agents, especially pyridine derivatives, using vitamin PP compounds, e.g. nicotinamide

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2362845A1 (en) * 1976-08-27 1978-03-24 Chinoin Gyogyszer Es Vegyeszet NEW O- (3-AMINO-2-HYDROXY-PROPYL) -AMIDOXIME DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO1990004584A1 (en) * 1988-10-20 1990-05-03 Biorex Kutató Fejleszto^' Kft. Novel o-(3-amino-2-hydroxypropyl)-hydroximic acid halides and process for preparing the same
WO1997013504A1 (en) * 1995-09-29 1997-04-17 Medgene Limited Pharmaceutical compositions containing hydroximic acid derivatives
WO1997016439A1 (en) * 1995-11-02 1997-05-09 Biorex Kutató és Fejlesztó Rt. Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof
DE19756236A1 (en) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Novel piperazinyl-substituted pyridylalkane, alkene and alkyarboxylic acid amides
DE19818044A1 (en) * 1998-04-22 1999-10-28 Klinge Co Chem Pharm Fab Reducing side effects or neutralizing action of carcinostatic or immunosuppressive agents, especially pyridine derivatives, using vitamin PP compounds, e.g. nicotinamide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VIGH L ET AL: "Bimoclomol: a nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects.", NATURE MEDICINE, (1997 OCT) 3 (10) 1150-4., XP000876870 *

Also Published As

Publication number Publication date
WO2000007580A2 (en) 2000-02-17
AU5296799A (en) 2000-02-28

Similar Documents

Publication Publication Date Title
CA2327723A1 (en) Bicyclic hydroxamic acid derivatives
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO1999064409A3 (en) Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use
CA2243504A1 (en) New 19-nor-pregnene derivatives
WO2001072728A3 (en) Novel piperazine derivatives
CA2274464A1 (en) Ketobenzamides as calpain inhibitors
CA2278201A1 (en) Novel modifications to 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonyl-aminobenzene, and processes for their preparation
CA2414018A1 (en) 2-aminocarbonyl-9h-purine derivatives
CA2343236A1 (en) 4,4-biarylpiperidine derivatives
CA2400268A1 (en) Pyrrolopyrimidinone derivatives, process of preparation and use
BG103268A (en) Propionic acid derivatives and their application
WO2002098856A3 (en) Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists
CA2475113A1 (en) Isothiazole derivatives useful as anticancer agents
CA2411754A1 (en) 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid and compositions for delivering active agents
CA2343732A1 (en) Substituted .gamma.-phenyl-.delta.-lactones and analogs thereof and uses related thereto
WO2000074677A3 (en) Improved pharmaceutical formulations
WO2000039083A3 (en) Pyrazole compounds and uses thereof
AU2001278821A1 (en) Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same
WO2002094020A8 (en) Use of triazolopyrimidine derivatives as microbicides in the protection of materials
CA2361402A1 (en) Bis-sulfonamides
WO2003051274A3 (en) Benzodiazepine derivatives, preparation thereof and use thereof
WO2001072263A3 (en) Use of ectoin or ectoin derivatives for protecting stress proteins in the skin
WO2002050067A3 (en) Pharmaceutical heterocyclic compounds
WO2002032901A3 (en) Bridged piperazine derivatives
WO1999012933A3 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase